GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation

Loading news article.

GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation | WAPE

GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation

Article summary

Related companies

Comments —